FGF3 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

210 results for “FGF3”

Trials

View all 161 →

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

65 participants · First posted Mar 26, 2025

The FGF/FGFR Signalling Pathway:

421 participants · First posted Oct 6, 2017

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

20 participants · First posted Sep 1, 2023

Drugs

View all 20 →

F1F3

FGFR3(INSERM)

FGFR prodrugs

News

View all 29 →

Rogaratinib Achieves 41.7% Response Rate in SDH-Deficient GIST, Demonstrating Breakthrough Efficacy for Previously Untreatable Tumor Subtype

TYRA-300: Novel FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer and Achondroplasia

Tyra Biosciences' FGFR3 Inhibitor TYRA-300 Shows Promise in Urothelial Cancer

Page 1 of 21